Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Swank Diet, Wahls Elimination Diet; Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 70 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Conditions: Multiple Sclerosis
Interventions: Wahls Paleo Plus, Wahls Diet; Other
Lead sponsor: Terry L. Wahls; Other
Eligibility: 30 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Relapsing Multiple Sclerosis
Interventions: No intervention; Other
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Smyrna, Georgia • Boston, Massachusetts + 2 more

Conditions: Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions: HP 13C pyruvate injection, MRI Scanner; Drug · Device
Lead sponsor: Ari Green; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, Covid-19 vaccine; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more

Conditions: Multiple Sclerosis
Interventions: LY3541860, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon-1beta (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Teriflunomide, Evobrutinib; Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more

Conditions: Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: HB-adMSCs, Placebo; Biological · Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: PIPE-307 Dose A, PIPE-307 Dose B, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Berkeley, California • Colorado Springs, Colorado + 15 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: GA Depot, Placebo; Drug · Other
Lead sponsor: Mapi Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more

Conditions: Multiple Sclerosis
Interventions: Placebo, BMS 188667 (Abatacept); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 10
States / cities: New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more

Conditions: Multiple Sclerosis
Interventions: Avonex; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions: Ublituximab; Drug
Lead sponsor: Neurology Center of New England P.C.; Other
Eligibility: 55 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, [F-18]PBR06; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate, Peginterferon Beta-1a, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Multiple Sclerosis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Long Beach, California • San Francisco, California • Raleigh, North Carolina + 3 more

Conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions: Siponimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 54
States / cities: Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more

Search by objective public record fields.

Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

Wahls Paleo Diet and Progressive Multiple Sclerosis

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

Assessing Tolerability of Avonex Intramuscular Injections

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients